Guardian Pharmacy Services, Inc. Class A (GRDN) AI Stock Analysis

• Market Cap: $1.80B
• Dividend Yield: N/A
• Average Volume (3M): 348.83K
• Price to Earnings (P/E): 44.6
• Beta (1Y): 0.63
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 3,400
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 0.25
• Shares Outstanding: 36,253,742
• 10 Day Avg. Volume: 450,542
• 30 Day Avg. Volume: 348,833
• PEG Ratio: 0.03
• Price to Book (P/B): 8.81
• Price to Sales (P/S): 1.02
• P/FCF Ratio: 30.20
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 1.20
• Enterprise Value/Gross Profit: 6.10
• Enterprise Value/Ebitda: 20.36
• 1Y Price Target: $34.50
• Price Target Upside: 17.59% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.97
• Revenue Forecast (FY): $1.43B

• Rating: 56 Neutral
• Price Target: $30.00 ▲(2.25% Upside)

Guardian Pharmacy Services' overall stock score reflects a mix of strong earnings performance and technical momentum, offset by significant financial risks and valuation concerns. The company's robust growth and strategic expansions are promising, but profitability and leverage issues, along with a high P/E ratio, present notable challenges.

Positive Factors

Revenue Growth

The 20% revenue growth reflects strong market demand and effective expansion strategies, ensuring sustained business development.

Strategic Acquisitions

Acquisitions in new regions enhance market presence and growth potential, reinforcing Guardian's competitive positioning.

Cash Generation

Strong cash generation provides financial flexibility for future investments and operational stability, supporting long-term growth.

Negative Factors

High Leverage

High leverage and lack of equity indicate financial risk, potentially affecting the company's ability to invest and grow sustainably.

Profitability Challenges

Ongoing profitability challenges may hinder Guardian's ability to reinvest in growth and maintain competitive advantages.

Regulatory Challenges

Regulatory challenges introduce operational uncertainties, potentially impacting Guardian's strategic initiatives and market operations.

Guardian Pharmacy Services, Inc. Class A Business Overview & Revenue Model

Company Description

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

How the Company Makes Money

Guardian Pharmacy Services generates revenue through multiple key streams. The primary source of income comes from the dispensing of prescription medications and over-the-counter products to long-term care facilities, where they have established contracts to serve as the preferred pharmacy provider. Additionally, the company earns fees from medication management services, which include consulting and compliance support for healthcare providers. Significant partnerships with healthcare organizations and payers enhance revenue stability, while the growing demand for specialized pharmacy services in the aging population drives further growth in earnings. By leveraging technology and optimizing pharmacy operations, Guardian Pharmacy also aims to reduce costs and increase efficiency, contributing positively to its revenue model.

Guardian Pharmacy Services, Inc. Class A Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.39B	1.23B	1.05B	908.91M	792.07M	735.96M
Gross Profit	274.32M	244.37M	208.31M	185.87M	161.26M	147.00M
EBITDA	82.19M	-43.43M	58.81M	68.15M	46.49M	49.07M
Net Income	40.24M	-87.29M	23.90M	35.42M	16.31M	19.94M
Balance Sheet
Total Assets	390.04M	320.81M	271.17M	256.11M	235.85M	217.87M
Cash, Cash Equivalents and Short-Term Investments	36.49M	4.66M	752.00K	607.00K	15.01M	6.45M
Total Debt	34.08M	37.33M	69.15M	62.98M	55.04M	58.84M
Total Liabilities	194.54M	170.83M	211.31M	180.18M	182.53M	150.80M
Stockholders Equity	183.76M	142.67M	28.21M	42.73M	23.93M	38.48M
Cash Flow
Free Cash Flow	45.21M	41.59M	56.26M	31.75M	49.22M	44.27M
Operating Cash Flow	59.82M	57.96M	70.82M	48.52M	58.50M	52.61M
Investing Cash Flow	-25.17M	-30.41M	-13.44M	-17.90M	-13.15M	-12.18M
Financing Cash Flow	-53.05M	-23.64M	-57.23M	-45.03M	-36.79M	-34.26M

Guardian Pharmacy Services, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 29.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRDN, the sentiment is Positive. The current price of 29.34 is above the 20-day moving average (MA) of 28.94, above the 50-day MA of 26.99, and above the 200-day MA of 23.50, indicating a bullish trend. The MACD of 0.43 indicates Positive momentum. The RSI at 57.16 is Neutral, neither overbought nor oversold. The STOCH value of 44.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRDN.

Guardian Pharmacy Services, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COR	76 Outperform	$71.49B	46.29	144.31%	0.61%	9.31%	5.92%
MCK	72 Outperform	$109.07B	27.51	―	0.36%	17.23%	66.17%
HSIC	69 Neutral	$8.86B	23.78	11.39%	―	3.51%	29.65%
CAH	64 Neutral	$50.64B	32.17	―	1.04%	4.37%	28.48%
GRDN	56 Neutral	$1.80B	44.56	25.85%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMI	39 Underperform	$212.70M	―	-184.47%	―	-37.09%	-2639.44%

Guardian Pharmacy Services, Inc. Class A Corporate Events

Guardian Pharmacy’s Earnings Call Highlights Growth and Challenges

Guardian Pharmacy Services, Inc. Class A recently held its earnings call, showcasing a strong financial performance and increased guidance for the year. The sentiment during the call was largely positive, driven by successful acquisitions and organic growth. However, the company faces challenges from regulatory pressures and the dilutive impact of recent acquisitions, which temper the otherwise optimistic outlook.

Guardian Pharmacy Services Boosts Revenue, Raises Guidance

Guardian Pharmacy Services, Inc. is a prominent player in the long-term care pharmacy services sector, providing medication and technology-enabled services to enhance care for residents in long-term care facilities across the United States. The company operates over 53 pharmacies nationwide, serving approximately 204,000 residents in 38 states.

Guardian Pharmacy Locks Up Majority of Shares

On October 14, 2025, Guardian Pharmacy Services, Inc. announced that it has entered into lock-up agreements with holders of approximately 93% of its outstanding Class A and Class B common stock. These agreements restrict the sale or transfer of shares held by the company’s founders, executive officers, and employees until June 30, 2026, impacting 17,188,059 Class A shares and 12,759,054 Class A shares issuable upon conversion of Class B shares. This move aims to stabilize the company’s stock following its initial public offering on September 27, 2024, and maintain market confidence.

The most recent analyst rating on (GRDN) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Guardian Pharmacy Services, Inc. Class A stock, see the GRDN Stock Forecast page.

Guardian Pharmacy Highlights Strategic Initiatives in ALF Market

Guardian Pharmacy Services, Inc. has released a presentation intended for investors and analysts, highlighting its strategic initiatives and market positioning. The company emphasizes its competitive advantages through a tech-enabled, service-led model, aiming for above-sector growth and profitability. The presentation outlines Guardian’s focus on the ALF market, which is characterized by a high demand for medication management due to the rising age and acuity of residents. The company’s strong financial performance, experienced management team, and significant market share position it as a leader in the highly fragmented ALF pharmacy market.

The most recent analyst rating on (GRDN) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Guardian Pharmacy Services, Inc. Class A stock, see the GRDN Stock Forecast page.